Loading...
Understanding mechanisms of resistance to cancer therapy allows for design of rational therapeutic strategies at disease progression and may offer insights to prevent or delay the onset of resistance. A prevalent target in cancer is KRAS, which is mutated in approximately 13% of lung adenocarcinomas and 3% of colorectal adenocarcinomas, far less in other solid tumors. Drug development to target KRAS has been challenging until recently, with two potent, selective, and irreversible small-molecule KRAS inhibitors (adagrasib and sotorasib) showing promising results in non–small-cell lung cancer (NSCLC) and more-modest activity in colorectal cancer (CRC).
Investigators conducted in-depth molecular analysis of tumor tissue or circulating tumor DNA…